Loading dashboard...
Peptide Assistant
Online
AI can make mistakes. Verify important medical data.
Press Enter to send
G
Medical Engine
Guest Account
AI can make mistakes. Verify important medical data.
Press Enter to send
Medical Engine
Guest Account
Loading dashboard...
From Ozempic to Retatrutide. Comparing the evolution of metabolic pharmacology.
Never start at maximum dose. Always begin with the lowest recommended dose (0.25mg Semaglutide, 2.5mg Tirzepatide). Titrate up weekly only if side effects are minimal. Starting too high can cause severe nausea, gastroparesis, and require medical intervention.
Comparing the current standard of care (Ozempic) against the incoming "Next Gen" compounds. From single agonists to triple-agonist "rocket ships."
| Feature | Semaglutide (Inj) | Rybelsus (Oral) | Tirzepatide | Retatrutide | CagriSema |
|---|---|---|---|---|---|
| Class | Mono (GLP-1) | Oral Mono (GLP-1) | Dual (GLP-1/GIP) | Triple (GLP/GIP/GCG) | Dual (GLP-1/Amylin) |
| Mechanism | Satiety | Satiety | Satiety + Insulin | Satiety + Energy Burn | Satiety + Physical Fullness |
| Weight Loss (16 weeks) | ~15% | ~15% | ~21% | ~24-29% | ~25% |
| Half-Life | 7 days | 24 hours | 5 days | 6 days | 7 days |
| Dosing Frequency | Weekly | Daily (Fasted) | Weekly | Weekly | Weekly |
| Starting Dose | 0.25mg | 3mg | 2.5mg | 2mg | Custom |
| Max Dose | 2.4mg | 50mg | 15mg | 12mg | Custom |
| Primary Side Effect | Nausea/Constipation | Nausea/Stomach Pain | Mild Nausea | Skin Sensitivity | Extreme Fullness |
| Heart Rate Impact | +2-4 bpm | +2-4 bpm | +3-5 bpm | +8-12 bpm | Neutral |
| Cost/Month (Typical) | $200-400 | $300-500 | $300-600 | $400-800 | $500-900 |
| Best For | Standard User | Needle Phobia | Metabolic Syndrome | Max Fat Loss | Anxiety/Heart Issues |
"Single Engine Plane"
"Twin Engine Jet"
"The Rocket Ship"
From The Drive - Episode #256
"If you lose weight on Ozempic without resistance training and protein, up to 40% of the weight lost is lean muscle tissue."
This accelerates sarcopenia (age-related muscle loss) and can leave you "skinny fat" with a lower metabolic rate than when you started.
Resting HR > 80bpm?
YES: Avoid Retatrutide.
NO: Proceed.
Need to lose >20% body weight?
YES: Retatrutide or CagriSema.
NO: Semaglutide is sufficient.
Prone to nausea?
YES: Tirzepatide (GIP buffers).
Users report a complete cessation of "Food Noise" (intrusive thoughts about food). Ideal for emotional eaters.
Massive metabolic rate increase. The weight melts off, but some users report *more* mental hunger than Tirzepatide.
GLP-1s can dampen dopamine.
Fix: Lower dose or stack with Tesofensine.
Shock from rapid weight loss.
Fix: Protein 1g/lb + Topical GHK-Cu.
Constipated > 3 days?
STOP. Do not layer more. Use Miralax.
Standard 16-Week Titration
Note: Increase dose weekly if tolerated. If nausea persists, stay at current dose an extra week.
Faster, Smoother Titration
Advantage: GIP buffers nausea, allowing faster titration. Most reach therapeutic dose by Week 12.
Stay at current dose. Do NOT titrate up until nausea resolves (usually 2-3 weeks).
No bowel movement for > 3 days? STOP the peptide. Use Miralax + Magnesium. Do NOT layer more compounds.
Skip next dose. Take 34g Miralax. Resume peptide in 2-3 days when regular.
GLP-1 (any) + BPC-157 (Oral 250mcg daily)
BPC heals gut lining, reducing nausea and gastroparesis risk. Essential for long-term GLP-1 use.
GLP-1 (low dose) + Tesofensine (0.5mg daily)
Tesofensine restores dopamine (prevents anhedonia) while maintaining weight loss. Prevents "Zombie Mode".
GLP-1 + Protein (1g/lb) + GHK-Cu (Topical 2mg/ml)
Prevents hair shedding from rapid weight loss. GHK-Cu stimulates follicle regeneration.
Multiple GLP-1 agonists (Semaglutide + Tirzepatide)
Competitive binding. No additional benefit, massive side effect risk.
Retatrutide + Stimulants (Caffeine, Ephedrine)
Heart rate spike can be dangerous. Retatrutide alone raises HR +10 bpm.
GLP-1 + Alcohol (Frequent/Heavy)
Pancreatitis risk increases. Gastroparesis worsens. Alcohol negates benefits.
| Compound | Starting Dose Cost | Max Dose Cost | Cost per % Weight Loss | Value Rating |
|---|---|---|---|---|
| Semaglutide | $200/mo | $350/mo | $23 | ⭐⭐⭐ |
| Tirzepatide | $300/mo | $550/mo | $26 | ⭐⭐⭐⭐ |
| Retatrutide | $400/mo | $750/mo | $26 | ⭐⭐⭐ |
| CagriSema | $500/mo | $850/mo | $34 | ⭐⭐ |
Note: Costs vary by source (pharmacy vs research peptides). These are typical ranges for 16-week cycles. Value rating based on efficacy-to-cost ratio and side effect profile.
Subject: Female, 50. Used Ozempic for 6 months, lost only 5lbs with constant nausea.
Protocol Change: Switched to Tirzepatide 5mg + BPC-157 (Oral 250mcg daily).
Result: Nausea resolved in 1 week. Weight loss accelerated to 1.5lbs/week.
GIP in Tirzepatide buffers nausea. BPC-157 heals gut, preventing gastroparesis.
Subject: Male, 45. On Semaglutide 2.4mg. Lost 40lbs but developed complete loss of motivation.
Protocol Change: Reduced to 1.0mg + Added Tesofensine (0.5mg daily).
Result: Motivation restored in 2 weeks. Weight loss continued at 0.5lbs/week.
High-dose GLP-1s can dampen dopamine. Tesofensine restores drive without hunger.
Retatrutide significantly raises resting heart rate (+8-12 bpm). If your baseline HR is > 80 bpm, avoid Retatrutide. Use Tirzepatide or CagriSema instead. Monitor HR weekly during cycle.
GLP-1 agonists carry a small but real risk of pancreatitis. If you experience severe abdominal pain, STOP immediately and seek medical attention. History of pancreatitis? Avoid all GLP-1s.
DO NOT use GLP-1 agonists if pregnant or planning pregnancy. Discontinue 2 months before attempting conception. Birth control required during use.
Use these biomarkers to monitor your metabolic health during GLP-1 therapy. Inspired by Peter Attia's longevity framework.
Key markers for insulin sensitivity and metabolic function
3-month glucose average. Optimal range for longevity.
Insulin sensitivity marker. Lower indicates better metabolic health.
Metabolic health indicator. Responds well to diet/exercise.
Wilding JPH, et al. • NEJM (2021)
Key Finding: ~14.9% mean weight loss at 68 weeks vs 2.4% placebo.
Jastreboff AM, et al. • NEJM (2022)
Key Finding: ~20.9% mean weight loss at 72 weeks (15mg dose).
Jastreboff AM, et al. • NEJM (2023)
Key Finding: ~24.2% mean weight loss at 48 weeks. Glucagon agonism increases energy expenditure.
"GLP-1 agonists are arguably the most impactful drugs of the century, but if you lose muscle while on them, you are trading diabetes for frailty. Resistance training is not optional."
Metabolic health and muscle preservation
— Outlive (2023)"If you're on a GLP-1 agonist and not doing resistance training, you're trading metabolic health for frailty. Muscle loss on these drugs is real and preventable with proper training."
GLP-1 agonists and muscle preservation
— The Drive Podcast"The next generation of metabolic therapeutics will be triple agonists like Retatrutide. Combining GLP-1, GIP, and Glucagon activation addresses multiple pathways simultaneously—not just appetite suppression, but actual metabolic rate enhancement."
Future of metabolic therapeutics
— The Drive Podcast